Alnylam Pharmaceuticals has reported a robust uptake of its RNA interference drug Amvuttra, approved for transthyretin amyloid cardiomyopathy (ATTR-CM). The therapy more than doubled sales year-over-year to $492 million in Q2, exceeding Wall Street expectations. The strong market penetration across both academic and community settings contributed to Alnylam's market capitalization surpassing $50 billion, signaling investor confidence in its rare disease portfolio.